Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Applied Therapeutics Inc (DE:2UV)
FRANKFURT:2UV
RESEARCH TOOLSreports
Holding DE:2UV?
Track your performance easily
2UV Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.88 - €9.49
Previous Close€0.88
Volume0.00
Average Volume (3M)1.02K
Market Cap
€113.79M
Enterprise Value€20.86M
Total Cash (Recent Filing)$98.90M
Total Debt (Recent Filing)$1.97M
Price to Earnings (P/E)―
Beta-1.03
Next Earnings
Mar 14, 2025EPS Estimate
-€0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding116,356,474
10 Day Avg. Volume310
30 Day Avg. Volume1,025
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)17.64
Price to Sales (P/S)11.88
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-98.85
Enterprise Value/Gross Profit2.09
Enterprise Value/Ebitda-0.11
Forecast
1Y Price Target
€4.34Price Target Upside392.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Applied Therapeutics News
Bulls Say, Bears Say
Bulls Say
Regulatory DevelopmentsThe late-cycle meeting with the FDA was collaborative, and the cancellation of the AdCom is seen as a favorable development, suggesting the NDA is on pace for approval.
Regulatory SupportNew FDA leadership at the rare disease division expressed support for an NDA, as they appeared to appreciate the totality of the data and high unmet need.
Stock PotentialThere was an expected share price return of over 310%, indicating significant potential upside.
Bears Say
Financial PerformanceFor third quarter 2024, Applied reported a net loss of $68.6 million.
Product Approval UncertaintyThe likelihood of non-approval for govorestat in galactosemia has increased, affecting the overall assessment.
Regulatory ChallengesThe FDA's warning letter has significantly affected management’s reputation, likely impacting near-term investor sentiment.
---
2UV FAQ
What was Applied Therapeutics Inc’s price range in the past 12 months?
Applied Therapeutics Inc lowest stock price was €0.88 and its highest was €9.49 in the past 12 months.
What is Applied Therapeutics Inc’s market cap?
Currently, no data Available
When is Applied Therapeutics Inc’s upcoming earnings report date?
Applied Therapeutics Inc’s upcoming earnings report date is Mar 14, 2025 which is in 82 days.
How were Applied Therapeutics Inc’s earnings last quarter?
Applied Therapeutics Inc released its earnings results on Nov 07, 2024. The company reported -€0.457 earnings per share for the quarter, missing the consensus estimate of -€0.15 by -€0.307.
Is Applied Therapeutics Inc overvalued?
According to Wall Street analysts Applied Therapeutics Inc’s price is currently Undervalued.
Does Applied Therapeutics Inc pay dividends?
Applied Therapeutics Inc does not currently pay dividends.
What is Applied Therapeutics Inc’s EPS estimate?
Applied Therapeutics Inc’s EPS estimate is -€0.19.
How many shares outstanding does Applied Therapeutics Inc have?
Applied Therapeutics Inc has 116,356,476 shares outstanding.
What happened to Applied Therapeutics Inc’s price movement after its last earnings report?
Applied Therapeutics Inc reported an EPS of -€0.457 in its last earnings report, missing expectations of -€0.15. Following the earnings report the stock price went down -2.93%.
Which hedge fund is a major shareholder of Applied Therapeutics Inc?
Among the largest hedge funds holding Applied Therapeutics Inc’s share is Perceptive Advisors LLC. It holds Applied Therapeutics Inc’s shares valued at 68M.
---
Applied Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.34 (392.28% Upside)
€4.34 (392.28% Upside)
Blogger Sentiment
Bullish
DE:2UV Sentiment 75%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
135.79%
Trailing 12-Months
Company Description
Applied Therapeutics Inc
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
---
2UV Stock 12 Month Forecast
Average Price Target
€4.34
▲(392.28% Upside)
Technical Analysis
Applied Therapeutics
―
AlloVir
―
Corvus Pharmaceuticals
―
Galera Therapeutics
―
Bicycle Therapeutics
―
Best Analysts Covering 2UV
1 Year
1 Year Success Rate
11/32 ratings generated profit
1 Year Average Return
+57.79%
reiterated a buy rating 23 days ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 34.38% of your transactions generating a profit, with an average return of +57.79% per trade.
---